- First-line nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients with advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 Chinese subgroup analysis 2-year follow-upShen, L.; Bai, Y.; Lin, X.; Li, W.; Wang, J.; Zhang, X.; Pan, H.; Bai, C.; Bai, L.; Cheng, Y.; Zhang, J.; Zhong, H.; Ba, Y.; Hu, W.; Xu, R.; Guo, W.; Qin, S.; Yang, N.; Lu, J.; Chanaga, C. Amaya; Soleymani, S.; Liu, T.被引 1
- Efficacy and safety of capecitabine as maintenance therapy after capecitabine-based combination chemotherapy for patients with advanced esophagogastric junction adenocarcinomaLu B; Bao L B; Sun Z; Hua Z L; Wang X; Qu C PEuropean Review for Medical and Pharmacological Sciences, 2015, 19(19): 3605-3612.
- ASO Visual Abstract: Early and Persistent Dysphagia Relief Predicts Tumor Response in Esophageal Squamous Cell Carcinoma Patients Treated with ImmunochemotherapyHuang, Shujie; Tang, Yong; Wu, Hansheng; Shi, Qiuling; Tang, Jiming; Ben, Xiaosong; Zhang, Dongkun; Xie, Liang; Zhou, Haiyu; Chen, Gang; Wang, Sichao; Gao, Zhen; Xie, Zefeng; Chen, Rixin*; Qiao, Guibin*Annals of Surgical Oncology, 2023.被引 1
期刊论文
ASO Visual Abstract: Adjuvant Chemotherapy for Patients with Adenocarcinoma of the Esophagogastric Junction: A Retrospective, Multicenter Observational Study
18阅读
